

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT

CSTONE'S PARTNER BLUEPRINT MEDICINES ANNOUNCES FDA APPROVAL OF AYVAKIT® (AVAPRITINIB) FOR ADULTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS

The partner of CStone Pharmaceuticals (the “**Company**” or “**CStone**”), Blueprint Medicines Corporation (“Blueprint Medicines”) announced on May 22, 2023 that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM). ISM is a rare hematologic disorder that can lead to a range of debilitating symptoms across multiple organ systems and a significant impact on patients’ quality of life.

Discovered by CStone’s partner Blueprint Medicines, AYVAKIT is a potent, selective and orally available inhibitor of KIT and PDGFRA mutant kinases. CStone has an exclusive collaboration and license agreement with Blueprint Medicines for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan.

Dr. Jason Yang, CEO and executive director of CStone said, “We are delighted to see the FDA approval of AYVAKIT for the treatment of ISM, which represents a significant step forward in improving the lives of patients living with the disease. AYVAKIT has been approved in China for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring the PDGFRA exon 18 mutation, including PDGFRA D842V mutations. We hope to bring this innovative treatment to a broader population of patients in China in the future.”

Detailed results from the PIONEER trial, including open-label extension study data showing the clinical benefits of AYVAKIT through 48 weeks of treatment, were presented in February 2023 at

the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. In addition, the detailed results from the PIONEER trial of AYVAKIT in patients with ISM were published on May 23, 2023 in NEJM Evidence, a journal affiliated with The New England Journal of Medicine Group.

For more details on the FDA approval of AYVAKIT in ISM, please go to <https://ir.blueprintmedicines.com/news-releases/news-release-details/fda-approves-ayvakitr-avapritinib-first-and-only-treatment>.

Trademarks

Blueprint Medicines, AYVAKIT and associated logos are trademarks of Blueprint Medicines Corporation.

About CStone

CStone is a biopharmaceutical company focused on research, development and commercialization of innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a management team with extensive experience in innovative drug development, clinical research, and commercialization. The Company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received seven NDA approvals for four drugs. CStone's vision is to bring innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, June 5, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.